FOXP1 and cardiac hypertrophy: In conclusion, this study demonstrates that simvastatin inhibits TGFβ in the endothelium by direct Klf2-meidated repression or through the endothelial Klf2-Foxp1 transcription factor network, and thereby alleviates the cardiac fibrosis associated with fibroblast proliferation, myofibroblast formation and ECM protein production, and ameliorates the pathological cardiac hypertrophy with an increase of cardiomyocyte size and reactivation of cardiac fetal genes.